4.0
Moderna, Inc. is a United States–based company operating in the healthcare sector, within the biotechnology industry. The company specializes in developing messenger RNA–based (mRNA) vaccines and therapeutics.
Moderna was founded in 2010 by Derrick Rossi, Noubar Afeyan, Kenneth Chien and Robert Langer, driven by scientific advances that demonstrated the potential of mRNA to prevent and treat disease.
The company’s portfolio includes vaccines and clinical-stage programs for infectious diseases, immunotherapies, personalized cancer treatments, rare-disease therapies and autoimmune-disease applications. Its proprietary mRNA platform enables rapid and adaptable product development.
Moderna gained global recognition with its COVID-19 vaccine, a milestone in modern biotechnology.
The company operates globally, with presence in the United States, Europe and Asia, supported by partnerships with governments, scientific institutions and international health organizations.
Its structure includes biomedical research, clinical-operations teams, biologics manufacturing, pharmaceutical logistics and scientific-support units.
Market factors affecting Moderna include regulatory oversight, biotechnology-sector competitiveness, clinical-research costs, global vaccine demand, public-health policies and advancements in molecular-platform technologies.
Moderna, Inc. is listed on the Nasdaq under the ticker MRNA.
History and when Moderna, Inc. was founded
Moderna, Inc. was founded in 2010 in Massachusetts to develop therapeutic applications of mRNA technology. Through the 2010s, the company expanded its research programs, built manufacturing platforms and developed scientific partnerships.
In 2018, Moderna completed its IPO on the Nasdaq, becoming one of the largest public offerings in biotechnology. In 2020, the company reached global prominence with its COVID-19 vaccine, mRNA-1273.
From 2020 to 2024, Moderna advanced its clinical pipeline, expanded manufacturing capacity and invested in new mRNA applications across infectious diseases, oncology and personalized therapeutics.
Additional Information
The Company Moderna Inc. (United States), is listed on Nasdaq with a market value of $ 10.13 Billions, having an equity of $ 9.33 Billions.
With a total of 1.300 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.
In the last 12 months the Company had a revenue of $ 2.20 Billions, which generated a loss in the amount of $ -3.12 Billions.
As for its main indicators, the Company has a P/E ratio of -3.25, a P/BV ratio of 1.09 and in the last 12 months the Company did not pay dividends.
The Company is traded internationally through the ticker MRNA.
